Get the Stockscreener App
8.573
0.25%
-0.013
Ars Pharmaceuticals Inc stock is traded at $8.573, with a volume of 38,848.
It is down -0.25% in the last 24 hours and up +2.88% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
See More
Previous Close:
$8.56
Open:
$8.5
24h Volume:
38,848
Relative Volume:
0.03
Market Cap:
$852.00M
Revenue:
$84.28M
Net Income/Loss:
$-171.30M
P/E Ratio:
-4.9347
EPS:
-1.7373
Net Cash Flow:
$-171.21M
1W Performance:
+7.41%
1M Performance:
+2.88%
6M Performance:
-1.96%
1Y Performance:
-40.95%
1-Day Range:
$8.465
$8.5885
1-Week Range:
$7.65
$8.635
52-Week Range:
$6.66
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.58 | 850.01M | 84.28M | -171.30M | -171.21M | -1.7373 |
VRTX
Vertex Pharmaceuticals Inc
|
425.25 | 107.83B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
701.98 | 73.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
792.20 | 48.72B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.24 | 39.51B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
294.41 | 32.66B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Northland Capital | Outperform |
| Nov-04-25 | Resumed | Roth Capital | Buy |
| Sep-04-25 | Initiated | Roth Capital | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-10-25 | Initiated | Oppenheimer | Outperform |
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
How The ARS Pharmaceuticals (SPRY) Narrative Is Shifting With Fresh Analyst Models And Approvals - Yahoo Finance
SPRY Stock Price, Quote & Chart | ARS PHARMACEUTICALS INC (NASDAQ:SPRY) - ChartMill
[ARS] SUPERNUS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] Eledon Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
[ARS] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] ARS Pharmaceuticals, Inc. SEC Filing - Stock Titan
ARS Pharmaceuticals (NASDAQ: SPRY) sets 2026 meeting, highlights neffy launch and cash runway - Stock Titan
[ARS] MADRIGAL PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] IRONWOOD PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] Oric Pharmaceuticals, Inc. SEC Filing - Stock Titan
ARS Pharmaceuticals, Inc. (SPRY) soars 7.1%: Is further upside left in the stock? - MSN
BlackRock (SPRY) files amendment showing 4.98% ownership - Stock Titan
Epinephrine Nasal Spray Approved for Severe Allergic Reactions in EU - respiratory-therapy.com
Avoiding Lag: Real-Time Signals in (SPRY) Movement - Stock Traders Daily
[ARS] REGENERON PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
[ARS] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
ARS Pharmaceuticals Q3 2025 Earnings Preview - MSN
[ARS] Vanda Pharmaceuticals Inc. SEC Filing - Stock Titan
[ARS] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] LB PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] IONIS PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] BIOCRYST PHARMACEUTICALS INC SEC Filing - Stock Titan
ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock? - Yahoo Finance
[ARS] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] Xenon Pharmaceuticals Inc. SEC Filing - Stock Titan
FDA Approves Neffy Needle-Free Epinephrine Nasal Spray for Younger Children - respiratory-therapy.com
[ARS] PMV Pharmaceuticals, Inc. SEC Filing - Stock Titan
[ARS] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
[ARS] Shuttle Pharmaceuticals Holdings, Inc. SEC Filing - Stock Titan
[ARS] Verrica Pharmaceuticals Inc. SEC Filing - Stock Titan
FDA Approves Expanded Use for ARS Pharmaceuticals Nasal Spray - HarianBasis.co
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver - Insider Monkey
Pharma-Bio Serv (PBSV) posts $9.0M revenue, margins lift in Europe - Stock Titan
ARS Pharmaceuticals (SPRY) Stock: Breakdown Signals (Nudges Up) 2026-04-16Social Momentum Signals - UBND thành phố Hải Phòng
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) - Sahm
neffy® Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions - Investing News Network
Health Canada approves neffy nasal spray for severe allergies By Investing.com - Investing.com Australia
William Blair Maintains ARS Pharmaceuticals(SPRY.US) With Buy Rating - Moomoo
Health Canada approves neffy nasal spray for severe allergies - Investing.com
Health Canada Approves neffy Nasal Spray for Anaphylaxis Treatment in Canada, Available Summer 2026 - Quiver Quantitative
neffy® (epinephrine nasal spray) Approved in Canada as the - GlobeNewswire
Discipline and Rules-Based Execution in SPRY Response - Stock Traders Daily
[ARS] Amphastar Pharmaceuticals, Inc. SEC Filing - Stock Titan
Q1 Earnings Forecast for SPRY Issued By Northland Securities - MarketBeat
Rally Mode: Can ARS Pharmaceuticals Inc sustain earnings growth2026 Reactions & Community Trade Idea Sharing Platform - baoquankhu1.vn
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):